You are about to action:

Object being modified by the action

Do you want to proceed?

Share Video Link

https://www.bitchute.com/video/lZOsal9sZa3C/

Click to copy, then share by pasting into your messages, comments, social media posts and websites.

Embed Video HTML

Click to copy, then add into your webpages so users can view and engage with this video from your site.

Share to Social Media

Share to social media by clicking on the quick share links.

Report Content

Reason

Please select the most appropriate reason from the list provided.

Note: For a more detailed description of each reason, see our Community Guidelines.

Additional Comments

Please add any additonal comments that will help with the assessment of your request.

Note: Copyright claims must contain all the items specified within the Copyright Policy.

Email Submissions

We also accept reports via email. Please see the Guidelines Enforcement Process for instructions on how to make a request via email.

Thank you for submitting your report

We will investigate and take the appropriate action.

Add to Playlist

KlaTV: Menschheit 2.0: Ärztin warnt vor neuer Impf-Technologie - Interview mit Frau Dr. Carrie Madej

Next video playing soon

Click to cancel

Autoplay has been paused

Click to watch next video

First published at 18:18 UTC on November 18th, 2020.

#corona
#impfung
#gefahr

LewHol

subscribers

BitChute Advertisement

Frau Dr. Carrie Madej ist eine Fachärztin der Inneren Medizin in den USA. Ihr besonderes Forschungsinteresse galt schon früh den Impfstoffen. Doch warum sind Covid-19-Impfstoffe problematischer als andere Impfstoffe? Befindet sich die Menschheit tatsächlich in einem großen Experiment? Warnt Frau Dr. Madej die ganze Menschheit zu Recht vor der kommenden gentechbasierten Impfung? Wer noch nie etwas von Hydrogel, Luziferase und dem internationalen Bill Gates-Patent 060606 im Zusammenhang mit der 5G-Technologie gehört hat, möge sich dieses Kla.TV-Interview mit der Whistleblower-Ärztin unbedingt ansehen und weiterverbreiten!

LESS